No segmentation disclosed for this filer. n/a
Medite Cancer Diagnostics, Inc. booked $6.8M in FY2017 revenue, contracting 26% year over year — slower than 75% of Healthcare companies we track, at a -100.0% net margin.
No filings loaded — no CIK (non-SEC filer).